D19.1: Benign neoplasm of mesothelial tissue of peritoneum
D19.1, benign neoplasm of mesothelial tissue of peritoneum, is listed as a covered diagnosis in 3 Medicare billing and coding articles that apply to 19 HCPCS Level II codes, including Q5129 (Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg), Q5126 (Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg), Q5118 (Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg). 4 of these codes have a 2026 DMEPOS fee schedule amount; E0783 pays $9,917.33 to $11,667.45 (NU) depending on the state. The articles come from 3 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.
HCPCS Level II codes with D19.1 as a covered diagnosis
| Code | Description | Medicare coverage | DMEPOS fee 2026 (state range) | Articles listing it |
|---|---|---|---|---|
| Q5129 | Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Carrier judgment | — | 1 |
| Q5126 | Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | Carrier judgment | — | 1 |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Carrier judgment | — | 1 |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | Special coverage instructions apply | — | 1 |
| J9035 | Injection, bevacizumab, 10 mg | Carrier judgment | — | 1 |
| J3590 | Unclassified biologics | Carrier judgment | — | 1 |
| C9257 | Injection, bevacizumab, 0.25 mg | Special coverage instructions apply | — | 1 |
| Q5160 | Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg | Carrier judgment | — | 1 |
| E0783 | Infusion pump system, implantable, programmable (includes all components, e.g., pump, catheter, connectors, etc.) | Special coverage instructions apply | $9,917.33–$11,667.45 (NU) | 1 |
| E0786 | Implantable programmable infusion pump, replacement (excludes implantable intraspinal catheter) | Special coverage instructions apply | $10,969.75–$11,380.88 (NU) | 1 |
| E0782 | Infusion pump, implantable, non-programmable (includes all components, e.g., pump, catheter, connectors, etc.) | Special coverage instructions apply | $5,200.92–$6,118.73 (NU) | 1 |
| E0785 | Implantable intraspinal (epidural/intrathecal) catheter used with implantable infusion pump, replacement | Special coverage instructions apply | $572.38–$673.39 (KF) | 1 |
| J7999 | Compounded drug, not otherwise classified | Special coverage instructions apply | — | 1 |
| J2278 | Injection, ziconotide, 1 microgram | Special coverage instructions apply | — | 1 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | Special coverage instructions apply | — | 1 |
| A4220 | Refill kit for implantable infusion pump | Special coverage instructions apply | — | 1 |
| J9200 | Injection, floxuridine, 500 mg | Special coverage instructions apply | — | 1 |
| A9585 | Injection, gadobutrol, 0.1 ml | Carrier judgment | — | 1 |
| Q9953 | Injection, iron-based magnetic resonance contrast agent, per ml | Special coverage instructions apply | — | 1 |
Medicare policy articles listing D19.1
- A52370: Billing and Coding: Bevacizumab and biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B); 8 Level II codes)
- A56695: Billing and Coding: Implantable Infusion Pump (Palmetto GBA (MAC - Part B); 9 Level II codes). LCD with the same title: L33461
- A57206: Billing and Coding: Lumbar MRI (Noridian Healthcare Solutions, LLC (MAC - Part A, MAC - Part B); 2 Level II codes). LCD with the same title: L34220
A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.
Other D19 diagnoses (Benign neoplasm of mesothelial tissue)
- D19.0 — Benign neoplasm of mesothelial tissue of pleura
Frequently asked questions
Does Medicare cover D19.1 (Benign neoplasm of mesothelial tissue of peritoneum)?
Medicare covers items and services, not diagnoses. 3 Medicare billing and coding articles list D19.1 as a covered diagnosis for 19 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.
Which HCPCS codes can be billed with ICD-10 D19.1?
The Level II codes from the policies most specific to this diagnosis are Q5129 (Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg, 1 article); Q5126 (Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg, 1 article); Q5118 (Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg, 1 article); Q5107 (Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg, 1 article); J9035 (Injection, bevacizumab, 10 mg, 1 article). Code choice depends on the item supplied; check each code's descriptor.
What does Medicare pay for equipment billed with D19.1?
Under the 2026 DMEPOS fee schedule (non-rural state fees): E0783 $9,917.33 to $11,667.45 (NU); E0786 $10,969.75 to $11,380.88 (NU); E0782 $5,200.92 to $6,118.73 (NU); E0785 $572.38 to $673.39 (KF). Medicare pays 80% of the allowed amount after the Part B deductible.
Which Medicare policy articles list D19.1?
A52370 (Billing and Coding: Bevacizumab and biosimilars); A56695 (Billing and Coding: Implantable Infusion Pump); A57206 (Billing and Coding: Lumbar MRI).
What is ICD-10-CM code D19.1?
D19.1 is the ICD-10-CM code for benign neoplasm of mesothelial tissue of peritoneum, in category D19 (Benign neoplasm of mesothelial tissue), chapter 2: Neoplasms.
Next steps
- Run a reimbursement report for a device billed under Q5129
- Watch Q5129 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q5129
Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.